Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?

NXC-201 is simply a specialized CAR-T compartment therapy designed to destruct the root of toxic airy chains successful patients. The attraction has already received respective high-priority regulatory labels, including Breakthrough Therapy and Orphan Drug designations from the FDA and EMA. If successful, it would go the archetypal FDA-approved attraction specifically for the relapsed/refractory signifier of this disease.

To pb the upcoming regulatory and commercialized phases, the institution appointed Dr. Richard Graydon arsenic Chief Medical Officer. Dr. Graydon brings extended acquisition from Merck and Johnson & Johnson, wherever helium oversaw the support of large oncology drugs similar Keytruda and Darzalex. His expertise is expected to beryllium captious arsenic Immix Biopharma Inc. (NASDAQ:IMMX) transitions from a clinical-stage institution to a commercialized entity pursuing the anticipated BLA filing.

Immix Biopharma Inc. (NASDAQ:IMMX) is simply a clinical-stage biotechnology institution focused connected treating relapsed/refractory AL Amyloidosis. Its pb candidate, NXC-201, is simply a BCMA-targeted CAR-T compartment therapy designed to destruct the root of toxic airy chains that origin organ failure.

While we admit the imaginable of IMMX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.